![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Eli Lilly and Company |
Information provided by: | Eli Lilly and Company |
ClinicalTrials.gov Identifier: | NCT00552227 |
The purpose of this study is to determine whether ruboxistaurin can reduce blood vessel inflammation associated with diabetes.
Condition | Intervention | Phase |
Diabetes Mellitus |
Drug: ruboxistaurin Other: placebo |
Phase I |
MedlinePlus related topics: | Diabetes Stress |
ChemIDplus related topics: | Ruboxistaurin |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | The Effect of Protein Kinase C (PKC) β Specific Inhibitor on Oxidant Stress in Patient With Type 2 Diabetes Mellitus |
Enrollment: | 48 |
Study Start Date: | September 2002 |
Study Completion Date: | July 2005 |
Arms | Assigned Interventions |
1: Experimental |
Drug: ruboxistaurin
oral 32 mg daily
|
2: Placebo Comparator |
Other: placebo
placebo
|
Ages Eligible for Study: | 35 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Hemoglobin A1c (HbA1c) ≥7% and ≤11%.
Exclusion Criteria:
United States, Pennsylvania | |||||
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 am to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |||||
Philadelphia, Pennsylvania, United States |
Eli Lilly and Company |
Principal Investigator: | Muredach Reilly, MD | University of Pennsylvania, Philadelphia |
Lilly Clinical Trial Registry 
![]()   |
Study ID Numbers: | 6038, B7A-MC-MBCZ |
First Received: | October 30, 2007 |
Last Updated: | October 30, 2007 |
ClinicalTrials.gov Identifier: | NCT00552227 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
![]() |